Source: European Medicines Agency (EU) | Revision Year: 2018 | Publisher: Shire Human Genetic Therapies AB, Vasagatan 7, 111 20, Stockholm, Sweden
Replagal 1 mg/ml concentrate for solution for infusion.
Concentrate for solution for infusion.
A clear and colourless solution.
1 ml of concentrate for solution for infusion contains 1 mg of agalsidase alfa*.
Each vial of 3.5 ml of concentrate contains 3.5 mg of agalsidase alfa.
* agalsidase alfa is the human protein α-galactosidase A produced in a human cell line by genetic engineering technology.
For the full list of excipients, see section 6.1.
Agalsidase alfa catalyses the hydrolysis of Gb3, cleaving a terminal galactose residue from the molecule. Treatment with the enzyme has been shown to reduce accumulation of Gb3 in many cell types including endothelial and parenchymal cells. Agalsidase alfa has been produced in a human cell line to provide for a human glycosylation profile that can influence uptake by mannose-6-phosphate receptors on the surface of target cells.
Sodium phosphate monobasic, monohydrate
Water for injections
3.5 ml of concentrate for solution for infusion in a 5 ml vial (Type I glass) with a stopper (fluoro-resin coated butyl rubber), a one piece seal (aluminium) and flip-off cap. Pack sizes of 1, 4 or 10 vials.
Not all pack sizes may be marketed.
Shire Human Genetic Therapies AB, Vasagatan 7, 111 20, Stockholm, Sweden
Date of first authorisation: 03/08/2001
Date of last renewal: 03/08/2006
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.